Silver Book Fact

Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.

Wagner E, Sandhu N, Newton K, McCulloch D, et al. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA. 2001; 285(2): 182-189. http://jama.ama-assn.org/cgi/content/abstract/285/2/182

Reference

Title
Effect of Improved Glycemic Control on Health Care Costs and Utilization
Publication
JAMA
Publisher
JAMA
Publication Date
2001
Authors
Wagner E, Sandhu N, Newton K, McCulloch D, et al
Volume & Issue
Volume 285, Issue 2
Pages
182-189
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…